Piramal Healthcare on Monday announced that it has bought world-wide rights for potential Alzheimer’s tracers developed by molecular-imaging and development. However, the deal amount was not disclosed. In the statement, Piramal mentioned that the company is shifting from making branded generic medicines to making exclusive patent protected products indicating their change in approach with regards […]
Continue Reading...
